Cancer Market Facts
The AntiCancer PDOX team has come together with a common goal –
to improve the outcomes of cancer therapy.
A Growing Problem
According to the American Cancer Society’s Cancer Facts & Figures 2017, there will be an estimated 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the US this year.
This is horrible news that can’t be sugar coated. Everyone’s life has been impacted by cancer and will continue to be.
But if we take a peek at the micro-trends, we can clearly see progress. According to the ACS, cancer peaked at 215 deaths per 100,000 persons in 1991. As of 2014, that rate had dropped to 161 per 100,000 (a decline of 25%), primarily because of reductions in smoking and improvements in early detection and treatment.
This decline translates into more than 2.1 million fewer cancer deaths over the past two decades – progress that is driven by rapid declines in death rates for the four most common cancer types – lung, colorectal, breast, and prostate.
Pipeline of Oncology Drugs in Clinical Development
According to The Global Oncology Trend Report, the pipeline of oncology drugs in clinical development has expanded by 63% over the past ten years. The chart above shows the growth of the late phase oncology pipeline from 2005-2006. Other key trends highlighted in the report:
- Oncology research and development activity remains concentrated on targeted therapies, which make up 87% of the late phase pipeline today.
- Targeted therapies include small molecule protein kinase inhibitors, biologic monoclonal antibodies, and a range of new mechanisms that can identify or block the cell processes that cause cancer cells to multiply.
- Particular focus is being placed on targeted therapies that use gene marker tests to indicate a greater likelihood of tumor response, or amplify the patient’s own immune response to target the cancer.
- Immunotherapies are one of the fastest growing areas within oncology R&D, and will undoubtedly make up a larger portion of the pipeline in 2020.
Cancer Medicine Market
Unfortunately, the worldwide incidence of cancer is expected to grow 75% by 2030. As a result, the cancer medicine market will reach $124.9B growing at a 7% Compound Annual Growth Rate (CAGR) by 2018. AntiCancer PDOX is targeting this market and the following sub-markets*:
- Precision Medicine, which will reach $88B by 2022.
- Personalized oncological and medical testing and analysis, which grew to $21B in 2016.
- Cancer and tumor profiling, which will reach $35B by 2018, growing at a CAGR of 18.5%.
- Personalized treatment
- Technological innovation
- Gene sequencing
- Precise imaging
- Government support & regulation
If you are interested in learning more about the cancer market and the PDOX opportunity, please contact us at firstname.lastname@example.org.
* Sources: Markets and Markets Research, PricewaterhouseCoopers, International Agency for Cancer Research, Global Precision Medicine Market.